In Situ Peptide Self-Assembly Augments Antibody Recruitment for Tumor Immunotherapy

Area of Science:

• Biotechnology
• Immunology
• Materials Science

Background:

• Innate immune regulation therapy efficacy relies on antibody binding to tumor cells.
• Limited tumor cell receptor expression poses a challenge for sufficient antibody recruitment.
• Activating innate immunity requires a high density of antibodies on tumor surfaces.

Purpose of the Study:

• To develop a peptide self-assembly antibody recruitment strategy (SARS) to enhance antibody binding and immune-mediated tumor cell killing.
• To investigate the efficacy of self-assembled peptides as antibody-recruiting nanomaterials for cancer immunotherapy.

Main Methods:

• Development of a peptide self-assembly antibody recruitment strategy (SARS) utilizing intermolecular non-covalent forces.
• Assessment of antibody recruitment capacity of assembled peptides compared to monomers.
• Evaluation of immune-mediated tumor cell killing effects in vitro and in vivo.

Main Results:

• The self-assembled peptide strategy (SARS) significantly increased antibody recruitment capacity by fivefold compared to monomers.
• A fivefold enhancement in immune-mediated tumor cell killing was observed.
• The strategy demonstrated effectiveness independent of high cell surface antigen expression.

Conclusions:

• Self-assembled peptides show potent antibody-recruiting and tumor cell-killing capabilities.
• The SARS strategy offers a promising approach to overcome limitations in current antibody-based cancer immunotherapies.
• Self-assembled peptides represent a novel nanomaterial with significant potential for cancer immunotherapy.